title: Management of actinic cheilitis using ingenol mebutate gel: A report of seven cases.
abstract: Actinic cheilitis (AC) can precede the development of squamous cell carcinoma of the lip, a location with high risk of invasiveness and metastasis. We communicate the good results that we obtained when treating seven patients suffering from AC with ingenol mebutate (IM) 0,015% concentration gel on three consecutive days. Three patients achieved complete clearance and four significant improvement. IM is a topical field treatment approved for actinic keratosis. To our knowledge, reported experience in the management of AC with IM is very limited. Local skin responses grade 3 were the main adverse event observed and they resolved in all patients without specific therapy within 1 to 2 weeks. IM is characterized by its rapid clinical effect, its favorable safety profile and its dosing period of only 3 days, shorter than with other field therapies. All these facts make it an attractive new therapy for AC, with need for further study.
authors.affiliation: a Department of Dermatology , Pontevedra Hospital , Pontevedra , Spain.
authors.forename: Ángeles
authors.initials: Á
authors.lastname: Flórez
authors.affiliation: a Department of Dermatology , Pontevedra Hospital , Pontevedra , Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: Batalla
authors.affiliation: a Department of Dermatology , Pontevedra Hospital , Pontevedra , Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: de la Torre
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002613:Cheilitis / Q000188:drug therapy*; D019468:Disease Management; D004224:Diterpenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005782:Gels; D006801:Humans; D008048:Lip Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: C486592:3-ingenyl angelate; D000970:Antineoplastic Agents; D004224:Diterpenes; D005782:Gels
keywords: actinic keratosis; local skin response; squamous cell carcinoma